| Cas No.: | 138356-21-5 |
| Chemical Name: | BD1047 HBr |
| Synonyms: | BD 1047 dihydrobromide;dihydrobromide;N'-[2-(3,4-dichlorophenyl)ethyl]-N,N,N'-trimethylethane-1,2-diamine;BD-1047 (dihydrobromide);BD1047.2HBr;N-[2-(3,4-Dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino)ethylamine dihydrobromide;BD1047dihydrobromide;BD1047 dihydrobromide;BCP15756;API0007828;AK200110;BD 1047 dihydrobromide, >=95% (HPLC);B6521;A13196;J-0;BD-1047 dihydrobromide |
| SMILES: | Br[H].Br[H].ClC1=C(C([H])=C([H])C(=C1[H])C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])[H])Cl |
| Formula: | C13H22Br2Cl2N2 |
| M.Wt: | 437.041 |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | BD-1047 dihydrobromide is a selective functional antagonist of sigma receptors, shows antipsychotic activity in animal models predictive of efficacy in schizophrenia. |
| In Vivo: | BD 1047 does not decrease amphetamine-induced hyperactivity in mice in a statistically significant manner. BD 1047 does not modify the hyperactivity induced by NMDA receptor antagonists. BD 1047 shows a moderate activity in models used in this study suggesting that its usefulness as an antipsychtic drug is doubtful. [1] |
| In Vitro: | Moreover, Progesterone and BD 1047 (a sigma 1 receptor antagonist) counteracted the antidepressant-like effect induced by co-administration of Pramipexole and Sertraline (but not Pramipexole and Fluoxetine). [2] This increased pNR1 expression is significantly reduced by pretreatment with the specific Sig-1 R antagonist, BD-1047. In another set of experiments Sig-1 R agonists further potentiated NMDA-induced pain behaviour and pNR1 immunoreactivity and this is also reversed with BD-1047. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|